Rheumatoid Arthritis

      Getting to the Heart of JAK Inhibitors
      3 years 4 months ago
      RT @drdavidliew: Looks like I’m not the only one who doesn’t let the absence of synovitis stop me from sometimes tre

      David Liew drdavidliew

      3 years 4 months ago
      Looks like I’m not the only one who doesn’t let the absence of synovitis stop me from sometimes treating high-risk clinically suspect arthralgias i.e. ‘very early early RA’ The truth comes out in anonymous surveys! #EULAR2022 @RheumNow https://t.co/BqTLy4HBWR
      EULAR,poster
      EULAR 2022 – Day 3 Report
      3 years 4 months ago
      By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
      EULAR 2022 - Day 3 Faculty Panel Recap
      3 years 4 months ago
      RT @ericdeinmd: Difficult to Treat RA (D2TRA): Jacob van Laar
      #EULAR2022 Points to consider @RheumNow
      1. Consider the d

      Eric Dein ericdeinmd

      3 years 4 months ago
      Difficult to Treat RA (D2TRA): Jacob van Laar #EULAR2022 Points to consider @RheumNow 1. Consider the diagnosis! Misdiagnosis or mimic? 2. U/s when in doubt 3. Caution in comorbidities (obesity, fm) which can overestimate inflamm markers, disease activity https://t.co/YT9NRv7EA0
      RA-ILD Lung Transplantation: Who Gets it and how do they do?
      3 years 4 months ago
      RT @jeffsparks: These findings suggest a pathogenic link between airway inflammation in bronchiectasis and RA-related au

      Jeffrey Sparks MD MMSc jeffsparks

      3 years 4 months ago
      These findings suggest a pathogenic link between airway inflammation in bronchiectasis and RA-related autoantibodies
      RT @KDAO2011: Prof van Lear noted 5-10% of pts have D2T RA; the highest risk factor is low socieconomic status. D2T RA h

      TheDaoIndex KDAO2011

      3 years 4 months ago
      Prof van Lear noted 5-10% of pts have D2T RA; the highest risk factor is low socieconomic status. D2T RA have higher comorbidities and healthcare utilization #EULAR2022 @rheumnow https://t.co/PhPjhksyI4 https://t.co/JCByho4ubk
      RT @jeffsparks: Associations with RA-BR (n=57 cases) compared to RA-no lung disease controls (n=36)
      ⬆️⬆️⬆️RF

      Jeffrey Sparks MD MMSc jeffsparks

      3 years 4 months ago
      Associations with RA-BR (n=57 cases) compared to RA-no lung disease controls (n=36) ⬆️⬆️⬆️RF level (OR 4.4) ⬆️⬆️ ACPA level (OR 3.5) ⬆️older age at RA onset (OR 1.37 per 10 years) ⬇️ BMI (OR 0.94 per kg/m2) (i.e., higher risk in underweight) 🚫 associations: sex, smoking pk-yrs
      Watch: New 2022 EULAR RA Treatment Guidelines

      https://t.co/mF4cKJLtbr

      #EULAR2022 https://t.co/oI8p6gL0Tf

      Dr. John Cush RheumNow

      3 years 4 months ago
      Watch: New 2022 EULAR RA Treatment Guidelines https://t.co/mF4cKJLtbr #EULAR2022 https://t.co/oI8p6gL0Tf
      RT @RichardPAConway: Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IM

      Richard Conway RichardPAConway

      3 years 4 months ago
      Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk @RheumNow #EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
      RT @RichardPAConway: More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0

      Richard Conway RichardPAConway

      3 years 4 months ago
      More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK
      RT @RichardPAConway: van der Pol et al from BeST study. No association with diabetes for pred use HR 0.588 (95%CI 0.285;

      Richard Conway RichardPAConway

      3 years 4 months ago
      van der Pol et al from BeST study. No association with diabetes for pred use HR 0.588 (95%CI 0.285; 1.21) nor cumulative pred dose OR 1.04 (95% CI 0.978; 1.13). Higher DAS assoc with diabetes. @RheumNow #EULAR2022 OP0272 https://t.co/QVjphcD7MG https://t.co/Buj8VAIJ5x
      RT @RichardPAConway: Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR202

      Richard Conway RichardPAConway

      3 years 4 months ago
      Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR2022 OP0277 https://t.co/oLmsrniKw6 https://t.co/2zDkuUzq0S
      RT @Janetbirdope: Are JAKi fulfilling their promises in RA? H Schulz-Koops said a survey showed rheumatologists wanted e

      Janet Pope Janetbirdope

      3 years 4 months ago
      Are JAKi fulfilling their promises in RA? H Schulz-Koops said a survey showed rheumatologists wanted effective fast acting Rx that could be used as monotherapy. ⁦⁦@eular_org⁩ #EULAR2022 ⁦@RheumNow⁩ https://t.co/Gdel9YnAzA

      Catch up on Conference Podcasts

      ×